Skip to main content
Erschienen in: Annals of Surgical Oncology 2/2015

01.02.2015 | Gynecologic Oncology

Positron Emission Tomography–Laparoscopy Based Method in the Prediction of Complete Cytoreduction in Platinum-Sensitive Recurrent Ovarian Cancer

verfasst von: Francesco Fanfani, MD, Giorgia Monterossi, MD, Anna Fagotti, MD, PhD, Valerio Gallotta, MD, Barbara Costantini, MD, Giuseppe Vizzielli, MD, Marco Petrillo, MD, Maria Vittoria Carbone, MD, Giovanni Scambia, MD

Erschienen in: Annals of Surgical Oncology | Ausgabe 2/2015

Einloggen, um Zugang zu erhalten

Abstract

Background

This study was designed to evaluate the positron emission tomography–laparoscopy-based method in the prediction of complete/optimal cytoreduction in platinum sensitive recurrent epithelial ovarian cancer patients.

Methods

We analysed 223 consecutive recurrent epithelial ovarian cancer patients. Inclusion criteria were absence of extra-abdominal disease and Eastern Cooperative Oncology Group Performance Status ≤2. Complete and optimal secondary cytoreduction are defined as macroscopic absence or less than 1 cm of residual tumor at the end of surgery.

Results

Laparoscopy was feasible in 210 of 223 patients (94.2 %). Laparoscopy stated 127 (60.5 %) possible cytoreductions and 83 (39.5 %) systemic chemotherapies. In the same population, AGO score evaluation avowed 150 possible cytoreduction (71.5 %) and 60 unresectable women (28.5 %). Overall, 115 of 210 patients (54.7 %) underwent successful secondary cytoreduction: complete and optimal cytoreduction was obtained in 103 (89.5 %) and 12 (10.5 %) patients, respectively. Laparoscopy obtained a positive predictive value of 91.3 %. Laparoscopy recovered to secondary cytoreduction 13 of 60 patients (21.7 %) deemed as not resectable according to AGO score. Forty-eight of 150 AGO score positive patients (32 %) were judged nonresectable by laparoscopy.

Conclusions

This study confirmed that laparoscopy could be effective for the selection of platinum-sensitive recurrent epithelial ovarian cancer patients suitable for complete cytoreduction.
Literatur
1.
Zurück zum Zitat Heintz APM, Odicino F, Maisonneuve P, et al. FIGO 26th annual report on the results of treatment in gynecological cancer. Int J Gynaecol Obstet. 2006;95:S161–92.PubMedCrossRef Heintz APM, Odicino F, Maisonneuve P, et al. FIGO 26th annual report on the results of treatment in gynecological cancer. Int J Gynaecol Obstet. 2006;95:S161–92.PubMedCrossRef
2.
Zurück zum Zitat du Bois A, Reus A, Pujade-Lauraine E, Harter P, Ray-Coquard I, Pfisterer J. Role of surgical outcome as prognostic factor in advanced epithelial ovarian cancer: a combined exploratory analysis of 3 prospectively randomized phase 3 multicenter trials: by the Arbeitsgeminsschaft Gynaekologiesche Onkologie Studiengruppe Ovarialkarzinom (AGO-OVAR) and the Groupe d’Investigateurs Nationaux Pour les Etude des Cancers de l’Ovarie (GINECO). Cancer. 2009;115:1234–44.PubMedCrossRef du Bois A, Reus A, Pujade-Lauraine E, Harter P, Ray-Coquard I, Pfisterer J. Role of surgical outcome as prognostic factor in advanced epithelial ovarian cancer: a combined exploratory analysis of 3 prospectively randomized phase 3 multicenter trials: by the Arbeitsgeminsschaft Gynaekologiesche Onkologie Studiengruppe Ovarialkarzinom (AGO-OVAR) and the Groupe d’Investigateurs Nationaux Pour les Etude des Cancers de l’Ovarie (GINECO). Cancer. 2009;115:1234–44.PubMedCrossRef
3.
4.
Zurück zum Zitat Al Rawahi T, Lopes AL, Bristow RE, et al. Surgical cytoreduction for recurrent epithelial ovarian cancer. Cochrane Database Syst Rev. 2013;28:CD008765. Al Rawahi T, Lopes AL, Bristow RE, et al. Surgical cytoreduction for recurrent epithelial ovarian cancer. Cochrane Database Syst Rev. 2013;28:CD008765.
5.
Zurück zum Zitat Harter P, Heitz F, du Bois A. Surgery for relapsed ovarian cancer: when should it be offered?. Curr Oncol Rep. 2012;14:539–43.PubMedCrossRef Harter P, Heitz F, du Bois A. Surgery for relapsed ovarian cancer: when should it be offered?. Curr Oncol Rep. 2012;14:539–43.PubMedCrossRef
6.
Zurück zum Zitat Harter P, Hahmann M, Lueck HJ, et al. Surgery for recurrent ovarian cancer: role of peritoneal carcinomatosis: exploratory analysis of the DESKTOP I trial about risk factors, surgical implications, and prognostic value of peritoneal carcinomatosis. Ann Surg Oncol. 2009;16:1324–30.PubMedCrossRef Harter P, Hahmann M, Lueck HJ, et al. Surgery for recurrent ovarian cancer: role of peritoneal carcinomatosis: exploratory analysis of the DESKTOP I trial about risk factors, surgical implications, and prognostic value of peritoneal carcinomatosis. Ann Surg Oncol. 2009;16:1324–30.PubMedCrossRef
7.
Zurück zum Zitat Harter P, Sehouli J, Reus A, et al. Prospective validation study of a predictive score for operability of recurrent ovarian cancer: the DESKTOP II study. A project of the AGO Kommission OVAR, AGO study group, NOGGO, AGO-Austria and MITO. Int J Gynecol Cancer. 2011;21:289–95.PubMedCrossRef Harter P, Sehouli J, Reus A, et al. Prospective validation study of a predictive score for operability of recurrent ovarian cancer: the DESKTOP II study. A project of the AGO Kommission OVAR, AGO study group, NOGGO, AGO-Austria and MITO. Int J Gynecol Cancer. 2011;21:289–95.PubMedCrossRef
8.
Zurück zum Zitat Funicelli L, Travaini LL, Landoni F, Trifirò G, Bonello L, Bellomi M. Peritoneal carcinomatosis from ovarian cancer: the role of CT and [18F] FDG-PET/CT. Abdom Imaging. 2010;35:701–7.PubMedCrossRef Funicelli L, Travaini LL, Landoni F, Trifirò G, Bonello L, Bellomi M. Peritoneal carcinomatosis from ovarian cancer: the role of CT and [18F] FDG-PET/CT. Abdom Imaging. 2010;35:701–7.PubMedCrossRef
9.
Zurück zum Zitat Bhosale P, Peungjesada S, Wei W, et al. Clinical utility of positron emission tomography/computed tomography in the evaluation of suspected recurrent ovarian cancer in the setting of normal CA-125 levels. In J Gynecol Cancer. 2010;20:936–44.CrossRef Bhosale P, Peungjesada S, Wei W, et al. Clinical utility of positron emission tomography/computed tomography in the evaluation of suspected recurrent ovarian cancer in the setting of normal CA-125 levels. In J Gynecol Cancer. 2010;20:936–44.CrossRef
10.
Zurück zum Zitat Fagotti A, Fanfani F, Rossitto C, et al. A treatment selection protocol for recurrent ovarian cancer patients: the role of FDG-PET/CT and staging laparoscopy. Oncology. 2008;75:152–8.PubMedCrossRef Fagotti A, Fanfani F, Rossitto C, et al. A treatment selection protocol for recurrent ovarian cancer patients: the role of FDG-PET/CT and staging laparoscopy. Oncology. 2008;75:152–8.PubMedCrossRef
11.
Zurück zum Zitat Fagotti A, Ferrandina G, Fanfani F, et al. Prospective validation of a laparoscopic predictive model for optimal cytoreduction in advanced ovarian carcinoma. Am J Obstet Gynecol. 2008;199:642.e1–6.CrossRef Fagotti A, Ferrandina G, Fanfani F, et al. Prospective validation of a laparoscopic predictive model for optimal cytoreduction in advanced ovarian carcinoma. Am J Obstet Gynecol. 2008;199:642.e1–6.CrossRef
12.
Zurück zum Zitat Vergote I, du Bois A, Amant F, Heitz S, Leunen K, Harter P. Neoadjuvant chemotherapy in advanced ovarian cancer: on what do we agree and disagree?. Gynecol Oncol. 2013;128:6–11.PubMedCrossRef Vergote I, du Bois A, Amant F, Heitz S, Leunen K, Harter P. Neoadjuvant chemotherapy in advanced ovarian cancer: on what do we agree and disagree?. Gynecol Oncol. 2013;128:6–11.PubMedCrossRef
13.
Zurück zum Zitat Stuart GC, Kitchener H, Bacon M, et al. 2010 Gynecologic Cancer InterGroup (GCIG) consensus statement on clinical trials in ovarian cancer: report from the Fourth Ovarian Cancer Consensus Conference. Int J Gynecol Cancer. 201;21:750–5. Stuart GC, Kitchener H, Bacon M, et al. 2010 Gynecologic Cancer InterGroup (GCIG) consensus statement on clinical trials in ovarian cancer: report from the Fourth Ovarian Cancer Consensus Conference. Int J Gynecol Cancer. 201;21:750–5.
14.
Zurück zum Zitat Zang RY, Harter P, Chi DS, et al. Predictors of survival in patients with recurrent ovarian cancer undergoing secondary cytoreductive surgery based on the pooled analysis of an international collaborative cohort. Br J Cancer. 2011;105:890–6.PubMedCentralPubMedCrossRef Zang RY, Harter P, Chi DS, et al. Predictors of survival in patients with recurrent ovarian cancer undergoing secondary cytoreductive surgery based on the pooled analysis of an international collaborative cohort. Br J Cancer. 2011;105:890–6.PubMedCentralPubMedCrossRef
15.
Zurück zum Zitat Fagotti A, Vizzielli G, De Iaco P, et al. A multicentric trial (Olympia-MITO 13) on the accuracy of laparoscopy to assess peritoneal spread in ovarian cancer. Am J Obstet Gynecol. 2013;209(5):462.e1–11.CrossRef Fagotti A, Vizzielli G, De Iaco P, et al. A multicentric trial (Olympia-MITO 13) on the accuracy of laparoscopy to assess peritoneal spread in ovarian cancer. Am J Obstet Gynecol. 2013;209(5):462.e1–11.CrossRef
16.
Zurück zum Zitat Fagotti A, Fanfani F, Vizzielli G, et al. Should laparoscopy be included in the work-up of advanced ovarian cancer patients attempting interval debulking surgery?. Gynecol Oncol. 2010;116:72–7.PubMedCrossRef Fagotti A, Fanfani F, Vizzielli G, et al. Should laparoscopy be included in the work-up of advanced ovarian cancer patients attempting interval debulking surgery?. Gynecol Oncol. 2010;116:72–7.PubMedCrossRef
17.
Zurück zum Zitat Fagotti A, Vizzielli G, Fanfani F, et al. Introduction of staging laparoscopy in the management of advanced epithelial ovarian, tubal and peritoneal cancer: impact on prognosis in a single institution experience. Gynecol Oncol. 2013;131:341–6.PubMedCrossRef Fagotti A, Vizzielli G, Fanfani F, et al. Introduction of staging laparoscopy in the management of advanced epithelial ovarian, tubal and peritoneal cancer: impact on prognosis in a single institution experience. Gynecol Oncol. 2013;131:341–6.PubMedCrossRef
18.
Zurück zum Zitat Magrina JF, Cetta RL, Chang YH, Guevara G, Magtibay PM. Analysis of secondary cytoreduction for recurrent ovarian cancer by robotics, laparoscopy and laparotomy. Gynecol Oncol. 2013;129:336–40.PubMedCrossRef Magrina JF, Cetta RL, Chang YH, Guevara G, Magtibay PM. Analysis of secondary cytoreduction for recurrent ovarian cancer by robotics, laparoscopy and laparotomy. Gynecol Oncol. 2013;129:336–40.PubMedCrossRef
19.
Zurück zum Zitat Gallotta V, Fagotti A, Fanfani F, et al. Laparoscopic surgical management of localized recurrent ovarian cancer: a single-institution experience. Surg Endosc. 2014;28(6):1808–15.PubMedCrossRef Gallotta V, Fagotti A, Fanfani F, et al. Laparoscopic surgical management of localized recurrent ovarian cancer: a single-institution experience. Surg Endosc. 2014;28(6):1808–15.PubMedCrossRef
20.
Zurück zum Zitat Sala E, Kataoka M, Pandit-Taskar N, et al. Recurrent ovarian cancer: use of contrast-enhanced CT and PET/CT to accurately localize tumor recurrence and to predict patients’ survival. Radiology. 2010;257:125–34.PubMedCentralPubMedCrossRef Sala E, Kataoka M, Pandit-Taskar N, et al. Recurrent ovarian cancer: use of contrast-enhanced CT and PET/CT to accurately localize tumor recurrence and to predict patients’ survival. Radiology. 2010;257:125–34.PubMedCentralPubMedCrossRef
21.
Zurück zum Zitat Chi DS, McCaughty K, Diaz JP, et al. Guidelines and selection criteria for secondary cytoreductive surgery in patients with recurrent, platinum-sensitive epithelial ovarian carcinoma. Cancer. 2006;106:1933–9.PubMedCrossRef Chi DS, McCaughty K, Diaz JP, et al. Guidelines and selection criteria for secondary cytoreductive surgery in patients with recurrent, platinum-sensitive epithelial ovarian carcinoma. Cancer. 2006;106:1933–9.PubMedCrossRef
22.
Zurück zum Zitat Tian W, Chi DS, Sehouli J, et al. A risk model for secondary cytoreductive surgery in recurrent ovarian cancer: an evidence-based proposal for patient selection. Ann Surg Oncol. 2012;19:597–604.PubMedCrossRef Tian W, Chi DS, Sehouli J, et al. A risk model for secondary cytoreductive surgery in recurrent ovarian cancer: an evidence-based proposal for patient selection. Ann Surg Oncol. 2012;19:597–604.PubMedCrossRef
Metadaten
Titel
Positron Emission Tomography–Laparoscopy Based Method in the Prediction of Complete Cytoreduction in Platinum-Sensitive Recurrent Ovarian Cancer
verfasst von
Francesco Fanfani, MD
Giorgia Monterossi, MD
Anna Fagotti, MD, PhD
Valerio Gallotta, MD
Barbara Costantini, MD
Giuseppe Vizzielli, MD
Marco Petrillo, MD
Maria Vittoria Carbone, MD
Giovanni Scambia, MD
Publikationsdatum
01.02.2015
Verlag
Springer US
Erschienen in
Annals of Surgical Oncology / Ausgabe 2/2015
Print ISSN: 1068-9265
Elektronische ISSN: 1534-4681
DOI
https://doi.org/10.1245/s10434-014-4011-0

Weitere Artikel der Ausgabe 2/2015

Annals of Surgical Oncology 2/2015 Zur Ausgabe

Update Chirurgie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

S3-Leitlinie „Diagnostik und Therapie des Karpaltunnelsyndroms“

Karpaltunnelsyndrom BDC Leitlinien Webinare
CME: 2 Punkte

Das Karpaltunnelsyndrom ist die häufigste Kompressionsneuropathie peripherer Nerven. Obwohl die Anamnese mit dem nächtlichen Einschlafen der Hand (Brachialgia parästhetica nocturna) sehr typisch ist, ist eine klinisch-neurologische Untersuchung und Elektroneurografie in manchen Fällen auch eine Neurosonografie erforderlich. Im Anfangsstadium sind konservative Maßnahmen (Handgelenksschiene, Ergotherapie) empfehlenswert. Bei nicht Ansprechen der konservativen Therapie oder Auftreten von neurologischen Ausfällen ist eine Dekompression des N. medianus am Karpaltunnel indiziert.

Prof. Dr. med. Gregor Antoniadis
Berufsverband der Deutschen Chirurgie e.V.

S2e-Leitlinie „Distale Radiusfraktur“

Radiusfraktur BDC Leitlinien Webinare
CME: 2 Punkte

Das Webinar beschäftigt sich mit Fragen und Antworten zu Diagnostik und Klassifikation sowie Möglichkeiten des Ausschlusses von Zusatzverletzungen. Die Referenten erläutern, welche Frakturen konservativ behandelt werden können und wie. Das Webinar beantwortet die Frage nach aktuellen operativen Therapiekonzepten: Welcher Zugang, welches Osteosynthesematerial? Auf was muss bei der Nachbehandlung der distalen Radiusfraktur geachtet werden?

PD Dr. med. Oliver Pieske
Dr. med. Benjamin Meyknecht
Berufsverband der Deutschen Chirurgie e.V.

S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“

Appendizitis BDC Leitlinien Webinare
CME: 2 Punkte

Inhalte des Webinars zur S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“ sind die Darstellung des Projektes und des Erstellungswegs zur S1-Leitlinie, die Erläuterung der klinischen Relevanz der Klassifikation EAES 2015, die wissenschaftliche Begründung der wichtigsten Empfehlungen und die Darstellung stadiengerechter Therapieoptionen.

Dr. med. Mihailo Andric
Berufsverband der Deutschen Chirurgie e.V.